|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:administered_by
|
over 300,000 individuals
|
|
gptkbp:approves
|
gptkb:FDA
gptkb:European_Medicines_Agency
|
|
gptkbp:associated_with
|
Bundibugyo ebolavirus
Sudan ebolavirus
Tai Forest ebolavirus
Zaire ebolavirus
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:United_States
West Africa
Phase 1
Phase 2
Phase 3
|
|
gptkbp:collaborated_with
|
gptkb:Médecins_Sans_Frontières
gptkb:African_Union
gptkb:United_Nations
gptkb:Gavi,_the_Vaccine_Alliance
|
|
gptkbp:community_health
|
increased awareness
saved lives
reduced transmission
strengthened healthcare systems
|
|
gptkbp:contains
|
Ebola virus glycoprotein
recombinant vesicular stomatitis virus
|
|
gptkbp:delivered_via
|
injection
|
|
gptkbp:demonstrated_efficacy
|
100% in clinical trials
|
|
gptkbp:developed_by
|
gptkb:Johnson_&_Johnson
gptkb:Merck_&_Co.
|
|
gptkbp:developed_in_response_to
|
2014 Ebola outbreak
|
|
gptkbp:emergency_services
|
granted in 2019
|
|
gptkbp:first_introduced
|
gptkb:2015
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ebola vaccine
|
|
gptkbp:is_funded_by
|
gptkb:World_Health_Organization
gptkb:National_Institutes_of_Health
|
|
gptkbp:long_term_effectiveness
|
under study
|
|
gptkbp:manufacturer
|
gptkb:Vaccine_Research_Center
|
|
gptkbp:part_of
|
global health security
Ebola response strategy
|
|
gptkbp:requires_booster
|
no
|
|
gptkbp:research_continues_on
|
new formulations
combination vaccines
improved delivery methods
longer-lasting immunity
|
|
gptkbp:side_effect
|
fatigue
headache
muscle pain
mild fever
injection site pain
|
|
gptkbp:storage
|
-60 to -80 degrees Celsius
|
|
gptkbp:suitable_for
|
pregnant women
immunocompromised individuals
|
|
gptkbp:target_audience
|
high-risk individuals
healthcare workers
outbreak responders
|
|
gptkbp:used_for
|
Ebola virus disease
|
|
gptkbp:bfsParent
|
gptkb:Merck_&_Co.
|
|
gptkbp:bfsLayer
|
4
|